We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.

For patients living with chronic respiratory diseases (CRDs) such as chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD), access to reliable and comprehensive health information is often limited and unreliable.

GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

As 2024 comes to a close and as the new Patient Advisory Board & Advocacy Manager at EUFOREA, I have the privilege to reflect on the achievements and milestones of EUFOREA this year. With my background as a pharmacist and scientific ...

As 2024 draws to a close, we’re celebrating a fantastic year of content.

A recent phase 2 trial published in The Lancet Respiratory Medicine has demonstrated that benralizumab, a monoclonal antibody targeting interleukin-5 receptor-α, can significantly reduce treatment failure in eosinophilic exacerbations of asthma and COPD.

The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.

The International Primary Care Respiratory Group (IPCRG) has initiated a global social movement to bring meaningful change in asthma management. The driving idea behind this initiative is a recognition that, while the current approach may feel sufficient to many, it falls short of optimal care. The IPCRG network sees clear evidence of avoidable harm and unnecessary costs in the current asthma management framework, which continue to impact lives and wellbeing.1 To counteract this, IPCRG's "Asthma Right Care" aims to inspire a shift towards better care practices by reducing both overuse and underuse of effective treatments. This means moving beyond episodic symptom relief and acute responses to establish a chronic care model that adheres to international or national asthma guidelines, prioritizing the appropriate use of anti-inflammatory inhaled medications.

A new European Respiratory Society (ERS) statement on preschool wheezing disorders represents a significant update in the approach to diagnosing and managing this complex condition in young children.